AU2002233271A1 - Substitued oxazoles and thiazoles as hppar alpha agonists - Google Patents

Substitued oxazoles and thiazoles as hppar alpha agonists

Info

Publication number
AU2002233271A1
AU2002233271A1 AU2002233271A AU3327102A AU2002233271A1 AU 2002233271 A1 AU2002233271 A1 AU 2002233271A1 AU 2002233271 A AU2002233271 A AU 2002233271A AU 3327102 A AU3327102 A AU 3327102A AU 2002233271 A1 AU2002233271 A1 AU 2002233271A1
Authority
AU
Australia
Prior art keywords
substitued
oxazoles
thiazoles
alpha agonists
hppar alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002233271A
Other languages
English (en)
Inventor
Michael Lawrence Sierra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2002233271A1 publication Critical patent/AU2002233271A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AU2002233271A 2000-12-20 2001-12-18 Substitued oxazoles and thiazoles as hppar alpha agonists Abandoned AU2002233271A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25707000P 2000-12-20 2000-12-20
US60257070 2000-12-20
PCT/EP2001/014886 WO2002050047A1 (en) 2000-12-20 2001-12-18 Substitued oxazoles and thiazoles as hppar alpha agonists

Publications (1)

Publication Number Publication Date
AU2002233271A1 true AU2002233271A1 (en) 2002-07-01

Family

ID=22974753

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002233271A Abandoned AU2002233271A1 (en) 2000-12-20 2001-12-18 Substitued oxazoles and thiazoles as hppar alpha agonists

Country Status (5)

Country Link
US (1) US7091225B2 (enrdf_load_stackoverflow)
EP (1) EP1345916A1 (enrdf_load_stackoverflow)
JP (1) JP2004517100A (enrdf_load_stackoverflow)
AU (1) AU2002233271A1 (enrdf_load_stackoverflow)
WO (1) WO2002050047A1 (enrdf_load_stackoverflow)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
GB0113233D0 (en) 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
GB0113232D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical process
WO2003015776A1 (en) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
ATE434616T1 (de) * 2001-10-12 2009-07-15 Nippon Chemiphar Co Aktivator des peroxisomproliferator-aktivierten rezeptors delta
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
KR100474202B1 (ko) * 2002-05-04 2005-03-08 강헌중 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체
MXPA05004191A (es) * 2002-10-21 2006-01-27 Johnson & Johnson Tetralinas e indanos sustituidos.
WO2004037777A1 (en) * 2002-10-21 2004-05-06 Janssen Pharmaceutica, N.V. Treating syndrome x with substituted tetralins and indanes
DK1554240T3 (da) * 2002-10-21 2009-08-17 Janssen Pharmaceutica Nv Substituerede tetraliner og indaner og deres anvendelse
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
EP2404605B1 (en) * 2004-08-25 2015-04-22 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
WO2006071103A1 (en) * 2004-12-31 2006-07-06 Heonjoong Kang Organoselenium containing compounds and their use
KR100797798B1 (ko) * 2005-02-25 2008-01-24 재단법인서울대학교산학협력재단 퍼록시솜 증식자 활성화 수용체 델타 리간드 티아졸 유도체및 그의 제조방법
EP2404604B1 (en) 2006-01-05 2019-02-06 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
EP2170341A4 (en) * 2007-07-02 2010-12-01 Essentialis Inc SALTS OF KALIUM ATP CHANNEL OPENERS AND ITS USES
US9479586B2 (en) * 2009-03-05 2016-10-25 Telecom Italia S.P.A. Distributed system for storing digital data

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4345230B2 (ja) * 1998-03-10 2009-10-14 小野薬品工業株式会社 カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
ATE318812T1 (de) * 2000-12-21 2006-03-15 Bristol Myers Squibb Co Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie

Also Published As

Publication number Publication date
WO2002050047A1 (en) 2002-06-27
US20040147571A1 (en) 2004-07-29
JP2004517100A (ja) 2004-06-10
US7091225B2 (en) 2006-08-15
EP1345916A1 (en) 2003-09-24

Similar Documents

Publication Publication Date Title
AU2002233271A1 (en) Substitued oxazoles and thiazoles as hppar alpha agonists
GC0000215A (en) Substituted oxazoles and thiazoles derivatives as hppar alpha activators
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
PL345882A1 (en) Substituted oxazoles and thiazoles derivatives as hppar gamma and hppar alpha activators
AU2002314744A1 (en) Thiazole and other heterocyclic ligands and use thereof
AU2002319320A1 (en) Substituted isoxazoles and the use thereof as antibiotics
AU2002349705A1 (en) Azole compound and medicinal use thereof
AU2710301A (en) Novel remedies with the use of beta3 agonist
AU2001233837A1 (en) Benzthiazoles as tnf and pde-iv inhibitors
AU2002216649A1 (en) Benzoxazole lpaat- beta inhibitors and uses thereof
AU2003225756A1 (en) Silica-based materials and methods
AU2001292285A1 (en) Thiazole or oxazole derivatives
AU2001248820A1 (en) Thiazole and oxazole derivatives
AU2001288972A1 (en) Antipsychotic sulfonamide-heterocycles, and methods of use thereof
ZA200108718B (en) Thiazolidinedione derivative and its use as antidiabetic.
AU2003299943A1 (en) Heterocycles and uses thereof
AU2002347985A1 (en) Peroxisome proliferator activated receptor alpha agonists
AU2001241498A1 (en) Matrix metalloproteinase inhibitors and uses thereof
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
AU2090202A (en) 1, 2, 4-oxadiazole derivatives as hppar alpha agonists
AU2002224772A1 (en) Morphinoid derivatives as delta-opioid agonists and antagonists
AU2001276258A1 (en) Ceramic component and the use thereof
SI1244642T1 (en) Substituted oxazoles and thiazoles derivatives as hppar alpha activators
AU2002352390A1 (en) Rosiglitazone citrate and its use as antidiabetic
AU2001268103A1 (en) Amorphous oxazole coumpound and its use as cox-2 inhibitor